Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 14, Issue 6, Pages 815-824
Publisher
Informa UK Limited
Online
2014-09-27
DOI
10.1586/14737167.2014.957682
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis
- (2016) David G Binion et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Concerns for severity in priority setting in health care: A review of trade-off data in preference studies and implications for societal willingness to pay for a QALY
- (2014) Erik Nord et al. HEALTH POLICY
- A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease
- (2014) J Dretzke et al. HEALTH TECHNOLOGY ASSESSMENT
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
- (2013) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
- (2013) Paweł Kawalec et al. Archives of Medical Science
- Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease
- (2013) Guillaume Bouguen et al. Clinical Gastroenterology and Hepatology
- American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
- (2013) Themistocles Dassopoulos et al. GASTROENTEROLOGY
- American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
- (2013) Jonathan P. Terdiman et al. GASTROENTEROLOGY
- A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease
- (2013) Derek H. Tang et al. INFLAMMATORY BOWEL DISEASES
- CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT
- (2013) Don Husereau et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease
- (2012) Francesc Casellas et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis
- (2012) Shota Saito et al. Journal of Crohns & Colitis
- Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease
- (2012) Derek H. Tang et al. PHARMACOTHERAPY
- Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis
- (2011) Ashwin N Ananthakrishnan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis
- (2011) Ashwin N. Ananthakrishnan et al. DIGESTIVE DISEASES AND SCIENCES
- Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
- (2011) Jennifer G. Gaultney et al. EUROPEAN JOURNAL OF CANCER
- Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
- (2011) Antonio Di Sabatino et al. Internal and Emergency Medicine
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease
- (2011) Gord Blackhouse et al. Journal of Crohns & Colitis
- Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adults
- (2010) J. LINDSAY et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A claims-based Markov model for Crohn’s disease
- (2010) D. C. Malone et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆
- (2010) Ambrogio Orlando et al. DIGESTIVE AND LIVER DISEASE
- Individual health discount rate in patients with ulcerative colitis
- (2010) Akbar K. Waljee et al. INFLAMMATORY BOWEL DISEASES
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis
- (2009) S. ODES et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data
- (2009) K. BODGER et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease
- (2009) Edward V. Loftus et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
- (2009) Filip Baert et al. GASTROENTEROLOGY
- Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohnʼs Disease
- (2009) Andrew P. Yu et al. PHARMACOECONOMICS
- Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease
- (2009) Yogesh Suresh Punekar et al. VALUE IN HEALTH
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started